Small molecule · developed by Xenon Pharmaceuticals
XPF-002 (also called XEN402) is a topical ointment applied to the skin twice daily. It has been studied in primary and inherited erythromelalgia, a rare disorder of painful, burning skin flushing in the extremities.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01486446 | Phase 1/2 | Primary Erythromelalgia | Completed | XENE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Inherited ErythromelalgiaPrimary Erythromelalgia
Updated Nov 1, 2026. Something wrong or missing? Report it on the XENE page.
See XENE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XENE catalysts and pipeline →